August 20, 2004Nephron Physiology

Combined Therapy of Cilazapril and Losartan Has No Additive Effects in Ameliorating Adriamycin-Induced Glomerulopathy

View Full Paper

Ask AI

Bookmark

Why the study?

Does combined therapy of cilazapril and losartan improve Adriamycin-induced glomerulopathy in rats compared to monotherapy?

Population

Male Sprague-Dawley rats (180-250 g) with Adriamycin (ADR)-induced glomerulopathy

Comparison

Cilazapril and/or losartan for 6 weeks vs Untreated ADR-induced glomerulopathy rats and…

Design

Preclinical

Follow-up

6 weeks

Authors

HKHo-Jung Kim JRJunho Ryu SHSang-Woong HanChina University of Political Science and Law

Discussion

Member takes

Implication

Combined ACEi+ARB shows no additive benefit in this rat model; leaves open translation to human proteinuric CKD.

Structured PICO

Does combined therapy of cilazapril and losartan improve Adriamycin-induced glomerulopathy in rats compared to monotherapy?

Population

Male Sprague-Dawley rats (180-250 g) with Adriamycin (ADR)-induced glomerulopathy

Intervention

Cilazapril (1 mg/kg/day) and/or losartan (10 mg/kg/day) for 6 weeks

Comparator

Untreated ADR-induced glomerulopathy rats and normal controls

Outcome

Urinary excretion of protein and glomerulosclerosis indexsurrogate

Combined ACEi and ARB therapy provides no additive benefit over monotherapy in ameliorating Adriamycin-induced glomerulopathy in rats.

Cite This Study

Kim et al. (2004) studied this question.

synapsesocial.com/papers/6a83f7fc5dc7077fe9c593e8 https://doi.org/10.1159/000079180

View Full Paper

Ask AI

Bookmark

Combined Therapy of Cilazapril and Losartan Has No Additive Effects in Ameliorating Adriamycin-Induced Glomerulopathy

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Combined Therapy of Cilazapril and Losartan Has No Additive Effects in Ameliorating Adriamycin-Induced Glomerulopathy

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider